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Abstract: Breast Cancer is the most prevalent cancer in the world with 4.4 million survivors up to 5 years following the diagnosis.1 In the 
US alone approximately forty thousand women die annually of metastatic breast cancer (MBC). Despite many effective systemic treatment 
options approximately 50% of women with MBC succumb to the disease within 24 months of the diagnosis.2 Ixabepilone is a novel, 
first in class member of the epothilone class of antineoplastic agents. Ixabepilone is indicated as monotherapy for the treatment of meta-
static or locally advanced breast cancer in patients whose tumors are resistant or refractory to anthracyclines, taxanes, and Capecitabine. 
Ixabepilone is also indicated in combination with Capecitabine for the treatment of patients with metastatic or locally advanced breast 
cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline 
therapy is contraindicated. Ixabepilone was extensively studied as a single agent in patients with MBC and was found to be effective and 
well tolerated with a predictable and manageable safety profile. Not surprisingly prior exposure to anthracyclines and taxanes affects 
significantly the potential for response to therapy with single agent Ixabepilone in metastatic setting. MBC patients with taxane resistant 
MBC have objective response rate (RR) of 12%, patients with prior low exposure to taxanes and/or resistance RR = 22%, Ixabepilone 
treatment after adjuvant anthracycline therapy exposure renders RR = 42% and in Taxane naïve patients RR = 57%. In two large phase 
III studies of Ixabepilone + Capecitabine versus Capecitabine alone, progression free survival (PFS) and overall response rates (RR) were 
higher in the combination treatment arms, but no survival advantage was seen overall.   Treatment with Ixabepilone + Capecitabine in a 
phase II study resulted in an overall response rate (ORR) of 23% in ER/PR/HER2 negative, triple-negative breast cancer patients (TNBC) 
while ORR of 31% was seen in a preplanned pooled analysis of TNBC in the phase III trials of Ixabepilone + Capecitabine. Significantly 
prolonged median PFS was seen for TNBC treated with the combination of Ixabepilone + Capecitabine compared to Capecitabine alone 
4.2 vs. 1.7 months respectively. Ixabepilone as single agent appears to show excellent antitumor activity in patients with TNBC MBC. 
Addition of Ixabepilone to Capecitabine results in approximately doubling in median PFS for TNBC versus Capecitabine alone. Single 
agent Ixabepilone is generally well tolerated, and its toxicity profile does not overlap with that of Capecitabine and therefore depending on 
prior exposure to chemotherapy both single agent Ixabepilone or in combination with Capecitabine can be used safely and effectively for 
treatment of advanced breast cancer.
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Introduction
Breast cancer is the most common malignancy diag-
nosed in women in the US2 and it is also a major 
global problem, with approximately 1 million cases 
occurring each year.1,3 Breast Cancer is the most prev-
alent cancer in the world with 4.4 million survivors up 
to 5 years following the diagnosis.1 Majority of women 
in the US present with early stage, potentially curable 
disease, only about 6% of newly diagnosed patients 
present with advanced or MBC.4 However, an esti-
mated 40% of patients initially presenting with local-
ized disease eventually progress to metastatic breast 
cancer.3 In the US alone approximately forty thousand 
women die annually of MBC and despite many effec-
tive systemic treatment options approximately 50% 
of women with MBC succumb to the disease within 
24  months  of  the  diagnosis.2  Recently  significant 
improvements  in  median  survival  with  MBC  have 
been noted from 1.28 yrs in 1991–1994 to 2.57 years 
in 2003–2006, this impressive increase in median sur-
vival appears to be primarily due to the effect of new 
systemic treatments introduced in recent years such as 
new hormonal treatments for MBC (HR = 0.72,); tax-
anes at first line (HR = 0.69,); trastuzumab at first line 
(HR = 0.63,).5 Many treatment options exist for MBC 
and the choice of systemic therapy depends on host 
and disease/tumor specific factors. Well established 
targets for therapy such as tumor expression of estro-
gen and/or progesterone receptors frequently preclude 
the use of endocrine manipulations first before chemo-
therapy is considered. Another established target for 
therapy in MBC is the HER2/neu which if amplified 
in the tumor mandates therapy with HER2 targeted 
agents such as Trastuzumab or Lapatinib in conjunc-
tion with chemotherapy.6–16 Majority of patients with 
MBC are offered systemic treatments to control/pal-
liate the symptoms of the disease soon after diagno-
sis is made. Based on NCCN guidelines patients with 
symptomatic  visceral  involvement  due    metastatic 
disease  such  as  liver,  lung  and  bone  marrow  are 
  recommended systemic   chemotherapy.17 Several che-
motherapy agents alone and in combination are FDA 
approved for management of MBC. As of October 
2007 Ixabepilone is one of newest US FDA approved 
antineoplastic agents for treatment of locally advanced 
and MBC. Ixabepilone is indicated as monotherapy 
for the treatment of metastatic or locally advanced 
breast cancer in patients whose tumors are resistant 
or refractory to anthracyclines, taxanes, and Capecit-
abine. Ixabepilone is also indicated in combination 
with Capecitabine for the treatment of patients with 
metastatic or locally advanced breast cancer resistant 
to treatment with an anthracycline and a taxane, or 
whose cancer is taxane resistant and for whom further 
anthracycline therapy is contraindicated.  Anthracycline 
resistance is defined as progression while on therapy 
or #6 months in the adjuvant setting or 3 months in the 
metastatic setting while taxane resistance is defined as 
progression while on therapy or #12 months in the 
adjuvant setting or 4 months in the metastatic setting.   
(http://packageinserts.bms.com/pi/pi_ixempra.pdf)
Mechanism of Action, Metabolism  
and Pharmacokinetic Profile
Mechanism of action
Ixabepilone is the first in class member of epothilone 
class of antineoplastic agents a relatively new class 
of antimicrotubule agents. Epothilones are cytotoxic 
macrolides  with  a  similar  mechanism  of  action  to 
paclitaxel but with the potential advantage of activ-
ity in taxane-resistant settings in preclinical models.18 
The antineoplastic activity of epothilones has been 
linked to stabilization of microtubules, which results 
in mitotic arrest at the G2/M transition. Ixabepilone 
(BMS-247550) is a semisynthetic analog of epothilone 
B  designed  to  optimize  the  characteristics  of  its 
natural precursor. It is distinct from other antineoplas-
tic agents because it has low susceptibility to com-
mon mechanisms of tumor resistance, including those 
mediated  by  P-glycoprotein  a  multidrug  resistance 
protein. In addition the microtubule-stabilizing agents 
such as Ixabepilone prolong activation of the spindle 
assembly checkpoint which may promote cancer cell 
death in mitosis or following mitotic exit.19 Significant 
alterations of dynamic instability of microtubules occur 
with a variety of antimitotic antineoplastic agents that 
interact with tubulin. A number of such compounds 
displaying great structural diversity are currently used 
in the clinic for treatment of solid tumor malignan-
cies and many of these agents were initially isolated 
from  natural  sources.20  Compounds  such  as  pacli-
taxel or docetaxel; complex diterpenes inhibit tubulin 
polymerization, and lead to mitotic arrest and stabili-
zation of microtubule assembly. The non-taxoid com-ixabepilone advanced breast cancer
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pounds, macrolides epothilones have also been shown 
to stabilize microtubules. The taxanes are widely used 
for  treatment  of  various  malignancies,  but  primary 
and acquired resistance to these antineoplastic agents   
remains a significant clinical concern.21 Class 1,2,3,4 
and 5 beta-tubulin isotypes are expressed in human 
tumors. Overexpression of the beta3-tubulin isotype is 
one mechanism that can render tumor cells resistant to 
taxanes. The significant antitumor activity of Ixabepi-
lone in taxane-resistant tumors may be related to its 
preferential suppression of the dynamic instability of 
alpha/beta3-microtubules in cells expressing high lev-
els of beta3-tubulin.22 Epothilone B analoge (EpoB) 
Ixabepilone has also been shown to induce apoptosis 
via a Bcl-2-suppressible pathway that controls a con-
formational change of the proapoptotic Bax protein. 
The enhanced cytotoxicity of EpoB by blocking Bcl-2 
at mitochondria implies a potential application of the 
combination  of  EpoB  and  Bcl-2  antagonists  in  the 
treatment of human breast cancer.21,23
Metabolism
Ixabepilone is metabolized in the liver and caution should 
be used when considering patients with liver impair-
ment  for  therapy  with  this  agent.  Ixabepilone  expo-
sure is greater in patients with hepatic impairment and 
those receiving concomitant strong cytochrome P-450 
CYP3A4 inhibitors. Dose adjustments and restrictions 
are recommended according to the degree of hepatic 
impairment,  whether  Ixabepilone  is  administered 
alone or in combination with Capecitabine if a strong 
CYP3A4 inhibitor is being coadministered.24 In patients 
without  liver  dysfunction  the  recommended  dose  of 
Ixabepilone  is  40  mg/m2  administered  intravenously 
(IV) over 3 hours every 3 weeks. Patients with mild 
hepatic impairment with AST and ALT #10 × upper 
limit  of  normal  (ULN)  and  bilirubin  #1.5  ×  ULN 
should be dose reduced to 32 mg/m2 every 3 weeks. For 
moderate liver dysfunction defined as AST and ALT 
#10 × ULN and bilirubin .1.5 × ULN #3 × ULN 
20–30 mg/m2 every 3 weeks should be used initially, 
or a dose of 20 mg/m2 can be used in the 1st cycle and, 
then in subsequent cycles Ixabepilone may be escalated 
up to, but not exceeding, 30 mg/m2 if tolerated. Use of 
Ixabepilone in patients with AST or ALT . 10 × ULN or 
bilirubin .3 × ULN is not recommended as limited data 
are available for patients with severe liver dysfunction.   
(http://packageinserts.bms.com/pi/pi_ixempra.pdf). 
The use of concomitant strong CYP3A4 inhibitors should 
be  avoided  (eg,  ketoconazole,  itraconazole,  clarithro-
mycin, atazanavir, nefazodone, saquinavir, telithromycin, 
ritonavir, amprenavir, indinavir, nelfinavir, delavirdine, 
or voriconazole). Coadministration of ketoconazole with 
Ixabepilone resulted in a 79% increase in area under the 
curve AUC.25 Grapefruit juice may increase plasma con-
centrations of Ixabepilone and should be avoided. The 
proposed mechanism is inhibition of CYP450 3A4-me-
diated first-pass metabolism in the gut wall by certain 
compounds present in grapefruits.
If a strong CYP3A4 inhibitor must be used a 50% 
dose reduction to 20 mg/m2 is required. On the other 
hand the use of concomitant strong CYP3A4 induc-
ers should also be avoided (eg, phenytoin, carbam-
azepine,  rifampin,  rifabutin,  dexamethasone,  and 
phenobarbital) because these can increase metabolism 
of Ixabepilone and decrease its efficacy. Markedly 
overweight patients with body surface area (BSA) 
greater than 2.2 m2 should have their dose calculated 
based on 2.2 m2 BSA. All patients should be moni-
tored closely while on treatment and therapy should 
be delayed to allow recovery from severe toxicities. 
Briefly the following guidelines can be considered 
for  Ixabepilone  monotherapy  and  in  combination 
with Capecitabine and include discontinuation of the 
agent/s for any grade 4 toxicity and unresolved grade 
3 neuropathy lasting for 7 days. Twenty percent 
dose adjustments are required for unresolved grade 
3 neuropathy lasting ,7 days or grade 2 neuropathy 
lasting for 7 days and any other grade 3 toxicity. If 
toxicities recur despite previous 20% dose reduction 
an additional 20% dose reduction should be made.
Pharmacokinetic profile
The pharmacokinetic profile of Ixabepilone and 2 of its 
chemical degradation products (the oxazine derivative 
BMS-249798 and the diol derivative BMS-326412) 
was assessed in a phase I dose escalation study for 1 and 
3-hour infusion and showed multiexponential drug dis-
position. Ixabepilone concentrations decreased to less 
than 10% of peak concentration by 8 hours from the 
start of the 1- or 3-hour infusion. The pharmacokinetic 
profile of Ixabepilone was similar during cycles 1 and 
2. Plasma concentrations of BMS-249798 and BMS-
326412 were much less than plasma concentrations of Tkaczuk
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Ixabepilone. Systemic exposure to BMS-249798 and 
BMS-326412 was less than 4% of systemic exposure 
to Ixabepilone.26 Another phase I study with Ixabepi-
lone  was  conducted  to  determine  pharmacokinetic 
profile and assess toxicities of the daily schedule for 
5 days every 21 days and showed that the mean ter-
minal half-life of Ixabepilone was 16.8 ± 6.0 hours, 
the volume of distribution at steady-state was 798 ± 
375 L, and the clearance was 712 ± 247 mL/min.27
Phase i studies of single  
agent ixabepilone
Various schedules of single agent Ixabepilone were 
studied in phase I, dose escalation studies to assess 
maximum tolerated dose (MTD), dose limiting toxic-
ity (DLT) and pharmacokinetic and pharmacodynamic 
profile of Ixabepilone in solid tumor malignancies and 
lymphomas. The following schedules were tested, 1 
and 3 hour infusion once every 21 days, 30 minutes 
weekly infusion continuous on 21 day schedule with-
out interruption weekly, 1 hour infusion 3 out of 4 
weeks every 28 days daily infusion on days 1–3 and 
1–5, every 21 days (Table 1). All schedules mentioned 
above showed acceptable and manageable side-effect 
profiles.
A  Phase  I  study  of  Ixabepilone  as  a  1-hour  iv 
daily for 3 consecutive days every 21 days (N = 26) 
was done. The starting dose of Ixabepilone was 8 or 
10 mg/m2 per day for 3 consecutive days. The MTD 
was 8 mg/m2 per day of Ixabepilone administered as a 
1-hour intravenous infusion daily iv for 3 consecutive 
days every 21 days. DLT was neutropenia, peripheral 
neuropathy was mild, even after multiple cycles of 
therapy, and was not dose limiting. Other nonhema-
tologic grade 3 toxicities included fatigue, hypona-
tremia, anorexia, ileus, stomatitis, and vomiting. The 
recommended Phase II dose of Ixabepilone on the 
daily schedule for 3 days was 8–10 mg/m2 per day.28 
Another phase I study of Ixabepilone as a 1-hour iv 
daily for 5 consecutive days every 21 days was con-
ducted (N = 27) without and with Filgrastim in the 
first cycle. The MTD was 6 mg/m2 administered as a 
1-hour iv daily for 5 consecutive days every 21 days. 
Neutropenia was the DLT at a dose of 8 mg/m2/d with 
or without filgrastim support. Other nonhematologic 
grade  3  toxicities  included  fatigue,  stomatitis,  and 
anorexia. The recommended phase II dose of Ixabepi-
lone on the daily schedule for 5 days was 6 mg/m2/d 
every 21 days. Peripheral neuropathy was mild, even 
after multiple cycles of therapy, and was not dose 
limiting.27
A phase I dose escalation study in patients (N = 61) 
with  advanced  solid  tumors  or  refractory  non-
Hodgkin’s lymphoma with Ixabepilone administered 
as a 1-hour infusion every 21 days.26 used an initial 
accelerated dose-escalation phase followed by a stan-
dard dose-escalation phase, with doses of Ixabepilone 
ranging from 7.4 to 65 mg/m2. The most common 
DLTs  were  neutropenia,  stomatitis/  pharyngitis, 
  myalgia, and arthralgia and the most frequent grade 
3/4 adverse events were sensory neuropathy (13%), 
fatigue (13%), myalgia (10%), arthralgia (7%), and 
nausea  (5%).  The  recommended  phase  II  dose  of 
Ixabepilone was 50 mg/m2 over 1 hour every 21 days 
and was initially used as the starting dose in phase II 
trials. However this dose was eventually decreased to 
40 mg/m2 over 3 hours every 21 days due to the early 
safety results which showed increased severe grade 3 
and 4 neuropathy with the 1 hour infusion schedule.
Another  single-arm,  dose-escalation  study  of 
Ixabepilone  delivered  as  30-min,  weekly  iv  on  a 
21-day  schedule  (N  =  33)  established  the  weekly 
dose of Ixabepilone of 25 mg/m2/week as the phase II 
recommended dose. Grade 3 fatigue was the DLT in 
2/4 patients treated at 30 mg/m2, overall Ixabepilone 
was well tolerated at the MTD and myelosuppression 
was rare, with no Grade 3/4 neutropenia. Due to the 
potential for cumulative neurotoxicity, the protocol 
was amended eventually to the following schedule, 
Ixabepilone  1-hour  infusion,  weekly  for  3  out  of 
4 weeks. No DLT occurred at starting doses of 15, 
20 and 25 mg/m2 on this modified schedule (N = 51), 
although overall toxicity was less at 15 and 20 mg/m2 
than 25 mg/m2. Ixabepilone had an acceptable safety 
profile at the MTD of 25 mg/m2 as a 30-min weekly 
infusion  on  a  continuous  21-day  schedule  and  at 
20 mg/m2 as a 1-hour weekly infusion on a modified 
28-day schedule.
Phase ii studies with single agent 
ixabepilone in locally advanced and MBC
Ixabepilone  was  extensively  studied  in  several 
phase II studies as a single agent in patients with 
MBC with various exposures to prior chemotherapy 
and  was  found  to  be  effective  and  well  tolerated 
with  a  predictable  and  manageable  safety  profile.   ixabepilone advanced breast cancer
Breast Cancer: Basic and Clinical Research 2011:5  5
T
a
b
l
e
 
1
.
 
P
h
a
s
e
 
i
 
s
t
u
d
i
e
s
 
w
i
t
h
 
s
i
n
g
l
e
 
a
g
e
n
t
 
i
x
a
b
e
p
i
l
o
n
e
 
a
n
d
 
i
x
a
b
e
p
i
l
o
n
e
 
w
i
t
h
 
c
a
p
e
c
i
t
a
b
i
n
e
.
A
u
t
h
o
r
D
o
s
e
 
r
a
n
g
e
 
 
a
n
d
 
s
c
h
e
d
u
l
e
n
u
m
b
e
r
 
 
o
f
 
p
t
s
 
(
n
)
R
e
c
o
m
m
e
n
d
e
d
 
 
p
h
a
s
e
 
I
I
 
d
o
s
e
M
a
x
i
m
u
m
 
 
t
o
l
e
r
a
t
e
d
 
d
o
s
e
D
o
s
e
 
l
i
m
i
t
i
n
g
 
 
t
o
x
i
c
i
t
i
e
s
A
g
h
a
j
a
n
i
a
n
2
6
7
.
4
 
t
o
 
6
5
 
m
g
/
m
2
,
 
 
1
-
h
o
u
r
 
i
n
f
u
s
i
o
n
 
 
e
v
e
r
y
 
3
 
w
e
e
k
s
6
1
5
0
 
m
g
/
m
2
,
 
1
 
h
o
u
r
 
e
v
e
r
y
 
 
2
1
 
d
 
t
h
i
s
 
d
o
s
e
 
w
a
s
 
 
e
v
e
n
t
u
a
l
l
y
 
d
e
c
r
e
a
s
e
d
 
t
o
 
 
4
0
 
m
g
/
m
2
 
o
v
e
r
 
3
 
h
o
u
r
s
 
 
e
v
e
r
y
 
2
1
 
d
 
d
u
e
 
t
o
 
e
a
r
l
y
 
 
s
a
f
e
t
y
 
s
i
g
n
a
l
s
 
s
h
o
w
i
n
g
 
 
i
n
c
r
e
a
s
e
d
 
s
e
v
e
r
e
 
 
g
r
a
d
e
 
3
–
4
 
n
e
u
r
o
p
a
t
h
y
 
 
w
i
t
h
 
t
h
e
 
1
 
h
o
u
r
 
 
i
n
f
u
s
i
o
n
 
s
c
h
e
d
u
l
e
5
0
 
m
g
/
m
2
 
1
-
h
o
u
r
 
 
i
n
f
u
s
i
o
n
 
e
v
e
r
y
 
2
1
 
d
N
e
u
t
r
o
p
e
n
i
a
,
 
 
s
t
o
m
a
t
i
t
i
s
,
 
 
p
h
a
r
y
n
g
i
t
i
s
 
 
m
y
a
l
g
i
a
,
 
 
a
r
t
h
r
a
l
g
i
a
Z
h
u
a
n
g
2
8
8
 
o
r
 
1
0
 
m
g
/
m
2
/
d
a
y
,
 
 
1
-
h
o
u
r
 
i
n
f
u
s
i
o
n
 
 
d
a
i
l
y
 
o
n
 
3
 
c
o
n
s
e
c
u
t
i
v
e
 
 
d
 
e
v
e
r
y
 
2
1
 
d
2
6
8
–
1
0
 
m
g
/
m
2
 
p
e
r
 
d
a
y
8
 
m
g
/
m
2
 
p
e
r
 
d
a
y
,
 
 
1
-
h
o
u
r
 
i
n
f
u
s
i
o
n
 
d
a
i
l
y
 
 
f
o
r
 
3
 
c
o
n
s
e
c
u
t
i
v
e
 
d
a
y
s
 
 
e
v
e
r
y
 
2
1
 
d
.
N
e
u
t
r
o
p
e
n
i
a
A
w
a
d
a
4
3
D
o
s
e
 
e
s
c
a
l
a
t
i
o
n
,
 
 
3
0
 
m
i
n
/
w
e
e
k
 
 
 
1
5
,
 
2
0
 
a
n
d
 
 
2
5
 
m
g
/
m
2
/
w
k
3
 
 
o
u
t
 
o
f
 
4
 
w
e
e
k
s
 
 
e
v
e
r
y
 
2
8
 
d
3
3
 
 
 
 
5
1
2
5
 
m
g
/
m
2
/
w
e
e
k
 
3
0
-
m
i
n
 
i
n
f
u
s
i
o
n
 
 
o
n
 
c
o
n
t
i
n
u
o
u
s
 
 
2
1
-
d
a
y
 
s
c
h
e
d
u
l
e
 
 
2
0
 
m
g
/
m
2
 
(
a
s
 
a
 
 
1
-
h
 
w
e
e
k
l
y
 
i
n
f
u
s
i
o
n
 
 
e
v
e
r
y
 
2
8
-
d
a
y
s
G
r
a
d
e
 
3
 
f
a
t
i
g
u
e
 
a
t
 
3
0
 
m
g
/
m
2
 
d
o
s
e
 
 
M
y
e
l
o
s
u
p
p
r
e
s
s
i
o
n
 
w
a
s
 
r
a
r
e
,
 
 
n
o
 
G
r
a
d
e
 
3
/
4
 
n
e
u
t
r
o
p
e
n
i
a
.
 
D
u
e
 
 
t
o
 
t
h
e
 
p
o
t
e
n
t
i
a
l
 
f
o
r
 
c
u
m
u
l
a
t
i
v
e
 
n
e
u
r
o
t
o
x
i
c
i
t
y
 
p
r
o
t
o
c
o
l
 
 
w
a
s
 
a
m
e
n
d
e
d
 
t
o
 
1
 
h
o
u
r
,
 
3
 
o
u
t
 
o
f
 
4
 
w
k
s
 
s
c
h
e
d
u
l
e
B
u
n
n
e
l
l
 
 
P
h
a
s
e
 
i
/
i
i
4
4
s
c
h
e
d
u
l
e
 
A
 
(
i
x
a
b
e
p
i
l
o
n
e
 
 
4
0
 
m
g
/
m
2
 
o
n
 
d
a
y
 
1
 
+
 
 
c
a
p
e
c
i
t
a
b
i
n
e
 
 
1
6
5
0
–
2
0
0
0
 
m
g
/
m
2
 
o
n
 
 
d
a
y
s
 
1
–
1
4
 
o
f
 
a
 
2
1
-
d
a
y
 
 
c
y
c
l
e
)
 
s
c
h
e
d
u
l
e
 
B
 
 
(
i
x
a
b
e
p
i
l
o
n
e
 
8
–
1
0
 
m
g
/
m
2
 
 
o
n
 
d
a
y
s
 
1
–
3
 
+
 
 
c
a
p
e
c
i
t
a
b
i
n
e
 
1
6
5
0
 
m
g
/
m
2
 
 
o
n
 
d
a
y
s
 
1
–
1
4
 
o
f
 
a
 
 
2
1
-
 
d
a
y
 
c
y
c
l
e
7
4
4
0
/
2
0
0
0
 
m
g
/
m
2
 
 
d
o
s
e
 
w
a
s
 
d
e
fi
n
e
d
 
a
s
 
 
t
h
e
 
M
T
D
 
f
o
r
 
 
s
c
h
e
d
u
l
e
 
A
 
N
o
 
(
D
L
T
s
)
 
w
e
r
e
 
 
o
b
s
e
r
v
e
d
 
i
n
 
 
t
h
e
 
1
6
5
0
 
m
g
/
m
2
 
 
a
n
d
 
1
6
5
0
 
m
g
/
m
2
 
 
c
o
h
o
r
t
s
G
r
a
d
e
 
3
 
p
l
a
n
t
a
r
-
p
a
l
m
a
r
 
 
e
r
y
t
h
r
o
d
y
s
e
s
t
h
e
s
i
a
 
(
P
P
e
)
 
 
G
r
a
d
e
 
3
/
4
 
T
r
e
a
t
m
e
n
t
-
r
e
l
a
t
e
d
 
 
e
v
e
n
t
s
 
i
n
 
p
h
a
s
e
 
i
i
 
f
a
t
i
g
u
e
 
 
(
3
4
%
)
,
 
P
P
e
 
(
3
4
%
)
,
 
m
y
a
l
g
i
a
 
 
(
2
3
%
)
,
 
n
a
u
s
e
a
 
(
1
6
%
)
,
 
 
p
e
r
i
p
h
e
r
a
l
 
n
e
u
r
o
p
a
t
h
y
 
(
1
9
%
)
,
 
 
d
i
a
r
r
h
e
a
/
v
o
m
i
t
i
n
g
 
(
1
0
%
)
.
 
G
r
a
d
e
s
 
3
/
4
 
n
e
u
t
r
o
p
e
n
i
a
 
(
6
9
%
)
 
 
a
n
d
 
l
e
u
k
o
p
e
n
i
a
 
(
5
5
%
)
 
w
e
r
e
 
 
m
a
n
a
g
e
d
 
p
r
i
m
a
r
i
l
y
 
b
y
 
d
o
s
e
 
 
r
e
d
u
c
t
i
o
n
/
t
r
e
a
t
m
e
n
t
 
i
n
t
e
r
r
u
p
t
i
o
n
A
b
r
a
h
a
m
2
7
D
o
s
e
 
e
s
c
a
l
a
t
i
o
n
 
d
a
i
l
y
 
 
f
o
r
 
5
 
c
o
n
s
e
c
u
t
i
v
e
 
d
a
y
s
 
 
e
v
e
r
y
 
2
1
 
d
2
7
d
a
i
l
y
 
s
c
h
e
d
u
l
e
 
f
o
r
 
5
 
d
 
 
i
s
 
6
 
m
g
/
m
2
/
d
6
 
m
g
/
m
2
 
i
v
 
d
a
i
l
y
 
 
f
o
r
 
5
 
c
o
n
s
e
c
u
t
i
v
e
 
 
d
a
y
s
 
e
v
e
r
y
 
2
1
 
d
N
e
u
t
r
o
p
e
n
i
a
 
w
i
t
h
 
(
8
m
g
/
m
2
/
d
)
o
r
 
 
w
i
t
h
-
o
u
t
 
fi
l
g
r
a
s
t
i
m
 
s
u
p
p
o
r
t
.
 
 
N
o
n
h
e
m
a
t
o
l
o
g
i
c
 
g
r
a
d
e
 
3
 
 
t
o
x
i
c
i
t
i
e
s
 
i
n
c
l
u
d
e
d
 
f
a
t
i
g
u
e
 
 
(
7
 
c
y
c
l
e
s
)
,
 
s
t
o
m
a
t
i
t
i
s
 
 
(
2
 
c
y
c
l
e
s
)
,
 
a
n
d
 
a
n
o
r
e
x
i
a
 
(
1
 
c
y
c
l
e
)
.Tkaczuk
6  Breast Cancer: Basic and Clinical Research 2011:5
Roche et al29 conducted a phase II single arm study 
of Ixabepilone in women with MBC (N = 65) who 
received  previously  an  anthracycline-based  regi-
men as adjuvant treatment. Ixabepilone was admin-
istered initially at 50 mg/m2 defined before iv over 
1 hour every 21 days but due to increased signals of 
toxicity (grade 3/4neuropathy) the infusion length 
was  increased  to  3  hours.  Later  due  to  increased 
rate  of  GI    toxicities  observed  in  another  phase  I 
study conducted in parallel the dose of Ixabepilone 
was decreased to 40 mg/m2 IV over 3 hours every 
21 days. Objective response rate (primary end point) 
for this study was 41.5% (95% CI, 29.4%–54.4%), 
median duration of response was 8.2 months (95% 
CI, 5.7–10.2 months), and median time to response 
was 6 weeks (range, 5–17 weeks). Median survival 
was  22.0  months  (95%  CI,  15.6–27.0  months). 
Treatment-related  adverse  events  were  manage-
able and mostly grades 1/2; the most common side 
effects other than alopecia were mild to moderate 
neuropathy, primarily sensory and mostly reversible 
in nature.29,30
Table 2. Phase ii single arm studies with ixabepilone in metastatic breast cancer, study endpoint overall response rate 
(ORR) for all studies.
Author Ixabepilone  
dose
patient  
population
number of  
patients
Overall  
response  
rates (ORR) 
(%) 
safety GR3/4  
toxicity  
in 10%  
of patients
THOMAS39 40 mg/m2,  
3 hour infusion  
q 21 d
Taxane-resistant 49 12% Fatigue-27%,  
Costitutional-27%  
Gi-20%,  
Neurology-14%  
sensory neuropathy-12%,
LOw33 6 mg/m2,  
1 hour infusion  
days 1–5  
q 21 d
Taxane-pretreated/ 
resistant
37 22%  
SD = 35%
Neutropenia (35%),  
Febrile neutropenia (14%), 
Fatigue (14%)  
Diarrhea (11%)  
Nausea/vomiting (5%),  
Myalgia/arthralgia (3%)  
Sensory neuropathy (3%)
ROCHe29 40 mg/m2  
3 hour infusion  
Q 21 d
Anthracycline- 
pretreated  
 
First-line  
metastatic
65 41.5% Neutropenia-58%  
Leucopenia-50%  
Sensory Neuropathy-20%  
Most common GR 1/2  
treatment-related adverse  
events other than alopecia   
included mild to moderate 
neuropathy, which was  
primarily sensory and  
mostly reversible.
DeNDULURi31,32 6 mg/m2/d,  
days 1–5  
1 hour infusion  
Q 21 d
Taxane-naive 23 57% Fatigue-13%  
Neutropenia-13%
BASeLGA42 40 mg/m2,  
3 hour infusion,  
Q 21 d
Neoadjuvant  
T 3 cm  
primary invasive  
breast cancer
161 in breast  
PCR = 18%  
PCR = 29%  
for eR-negative  
eR gene  
expression  
(eR1) was  
inversely  
related to  
pCR in breast
Grade 3 to 4 adverse  
events (Aes) were  
reported for 32% of pts.  
except for neutropenia  
and leukopenia, all  
grade 3 to 4 Aes  
occurred in #3%  
of patients. Reversible  
peripheral neuropathy  
was experienced by 3%  
of patients.ixabepilone advanced breast cancer
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A  phase  II  study  of  Ixabepilone  in  patients 
with Taxane-naive  MBC  (N  =  23)  used  a  differ-
ent Ixabepilone schedule; 6 mg/m2/d IV on days 1 
through 5 every 21 days until unacceptable toxicity 
or disease progression.31 In addition patients under-
went pre and post-treatment tumor tissue biopsies 
which were analyzed for acetylated -tubulin, tau-1, 
and p53 expression. Partial responses were seen in 
13  patients  (57%;  95%  CI,  34.5%–76.8%)  and  6 
patients (26%) had stable disease, median time to 
progression and duration of response were 5.5 and 
5.6 months respectively. Dose reductions for neu-
tropenia, neuropathy, or fatigue were required in a 
minority of patients and grade 3/4 toxicities were 
uncommon  and  included  neutropenia,  fatigue, 
anorexia and motor neuropathy. Grade 1/2 periph-
eral sensory neuropathy was seen in 52% of patients 
but no patient experienced grade 3/4 sensory neu-
ropathy.  Six  out  of  23  patients  had  paired  biop-
sies  pre  and  post  treatment  with  Ixabepilone  and 
all had increases in tumor-tubulin acetylation after 
treatment  however  baseline  or  cycle  2  acetylated 
-tubulin, tau-1, or p53 expression did not correlate 
with clinical response. The authors concluded that 
women with Taxane-naive MBC have a meaningful 
and  durable  response  to  single-agent  Ixabepilone 
therapy with minimal hematologic toxicity and no 
grade 3/4 sensory neuropathy noted.32
In another phase II study of single agent Ixabepi-
lone delivered at 6 mg/m2/day IV on days 1–5 every 
21  days,  women  with  MBC  (N  =  37)  with  mea-
surable disease who had paclitaxel and/or docetaxel 
as prior neoadjuvant, adjuvant, or metastatic therapy 
were treated.33 One hundred fifty three cycles were 
delivered, in this previously taxane exposed patient 
population 8 out of 37 (22%) patients had objective 
response; complete response was seen in 1 patient 
(3%), partial responses in 7 (19%), and stable dis-
ease in 13 (35%) patients. Again the most common 
grade  3/4  toxicities  included  neutropenia  (35%), 
febrile neutropenia (14%), fatigue (14%), diarrhea 
(11%),  nausea/vomiting  (5%),  myalgia/arthralgia 
(3%), and sensory neuropathy (3%). Two patients 
discontinued therapy with Ixabepilone due to pro-
longed grade 2 or 3 neurotoxicity, and 3 patients due 
to other grade 3 and 4 nonhematologic toxicities.
Efficacy and safety of Ixabepilone was studied by 
Perez  and  colleagues34  in  a  multicenter  single  arm 
phase II study in patients with MBC (N = 126) resistant 
to  an  anthracycline,  a  taxane,  and  Capecitabine. 
Patients  with  measurable  disease  who  progressed 
while receiving prior therapy with anthracycline, tax-
ane, and Capecitabine were treated with Ixabepilone 
40 mg/m2 monotherapy as a 3-hour IV every 3 weeks. 
The primary end point was objective response rate 
(ORR), assessed by an independent radiology facility 
(IRF). Off 126 treated patients 113 were assessable for 
response. Participants were “heavily pretreated”, 88% 
had received at least two lines of prior chemother-
apy in the metastatic setting. IRF-assessed ORR was 
11.5% (95% CI, 6.3%–18.9%) for response-assessable 
patients,  while  investigator-assessed  ORR  for  all 
treated patients was 18.3% (95% CI, 11.9%–26.1%). 
Fifty percent of patients achieved stable disease (SD) 
and 14.3% achieved SD 6 months. Median duration 
of  response  and  progression-free  survival  were  5.7 
and 3.1 months, respectively with a median overall 
survival of 8.6 months. Median of 4.0 treatment cycles 
(range, 1–16 cycles) were delivered, and a quarter of 
patients  received  8  cycles.  Grade  3/4  treatment-
related  toxicity  events  included  peripheral  sensory 
neuropathy (14%) and resolution of grade 3 and 4 
peripheral sensory neuropathy occurred after a median 
period of 5.4 weeks. Fatigue/asthenia (13%), myalgia 
(8%), and stomatitis/mucositis (6%) were the other 
most common grade 3 and 4 toxicities. The authors 
concluded that Ixabepilone demonstrated clear activity 
and a manageable safety profile in patients with MBC 
resistant to anthracycline, taxane, and Capecitabine, 
durable responses were observed in patients who pre-
viously did not respond to multiple other therapies.
combination of Ixabepilone  
and capecitabine in Metastatic  
Breast cancer
Effective  treatment  options  for  patients  with  meta-
static  breast  cancer  resistant  to  anthracyclines  and 
taxanes  are  limited.  Ixabepilone  has  single-agent 
activity  in  this  patient  population  and  preclinical 
synergy with Capecitabine has been demonstrated.35 
Two  large  phase  III  studies  were  done  to  evaluate 
efficacy of Ixabepilone in combination with Capecit-
abine in MBC patients, in both trials the control arm 
consisted of Capecitabine 2500 mg/m2 total daily dose 
in 2 divided doses on days 1–14 of a 21 day treatment 
cycle. Neither trial was designed to allow crossover Tkaczuk
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to single agent Ixabepilone treatment at the time of 
progression on Capecitabine. In an international phase 
III study Thomas et al35 studied the efficacy of the 
combination of Ixabepilone + Capecitabine compared 
to Capecitabine alone in patients with anthracycline-
pretreated or -resistant and taxane-resistant expousre 
locally advanced or MBC, up to 3 lines of prior che-
motherapy  exposure  were  allowed.  Seven  hundred 
fifty-two patients were randomly assigned to Ixabepi-
lone 40 mg/m2 given IV over 3 hours on day 1 of a 
21-day cycle + Capecitabine 2,000 mg/m2 orally on 
days 1 through 14 of a 21-day cycle, or Capecitabine 
alone 2,500 mg/m2 on the same schedule. The primary 
end point was progression-free survival (PFS) evalu-
ated  by  blinded  independent  review.  Ixabepilone  + 
Capecitabine  treatment  resulted  in  prolonged  PFS 
relative to Capecitabine (median, 5.8 v 4.2 months), 
with a 25% reduction in the estimated risk of dis-
ease progression (hazard ratio, 0.75; 95% CI, 0.64 
to  0.88;  P  =  0.0003).  Objective  response  rate  was 
also  increased  with  the  combination  (35%  v  14%; 
P  ,  0.0001).  Grade  3/4  treatment-related  sensory 
neuropathy (21% v 0%), fatigue (9% v 3%), and neu-
tropenia (68% v 11%) were more frequent with com-
bination therapy. Capecitabine-  related toxicities were 
similar for both treatment groups. The investigators 
concluded that Ixabepilone + Capecitabine combina-
tion demonstrated superior efficacy to Capecitabine 
alone in patients with MBC pretreated or resistant to 
anthracyclines and resistant to taxanes.
The second large 2 arm phase III trial was done to 
compare the efficacy of the combination of  Ixabepi-
lone + Capecitabine with Capecitabine alone.36 In this 
study the investigators sought to determine whether the 
combination of Ixabepilone + Capecitabine improved 
overall  survival  (OS)  compared  with  Capecitabine 
alone in patients with MBC previously treated with 
anthracyclines and taxanes, up to 2 lines of prior ther-
apy were allowed. A total of 1,221 patients with MBC 
previously  treated  with  anthracycline  and  taxanes 
were randomly assigned to Ixabepilone (40 mg/m2   IV 
on day 1) +   Capecitabine (2,000 mg/m2 orally on days 
1 through 14) or Capecitabine alone (2,500 mg/m2 on 
the same schedule) given every 21 days. The trial 
was powered to detect a 20% reduction in the hazard 
ratio (HR) for death. There was no significant differ-
ence in OS between the combination of Ixabepilone + 
Capecitabine and Capecitabine monotherapy arm, the 
median survival was 16.4 v 15.6 months respectively, 
HR = 0.9; 95% CI, 078 to 1.03; P = 0.1162). The 
treatment arms were well balanced with the excep-
tion of a higher prevalence of impaired performance 
status  (Karnofsky  performance  status-KPS  70%  to 
80%) in the combination arm (32% v 25%). In a sec-
ondary Cox regression analysis adjusted for perfor-
mance status and other prognostic factors, OS was 
improved for the combination (HR = 0.85; 95% CI, 
0.75–0.98; P = 0.0231). Patients with measurable dis-
ease (79%) treated with the combination had a sig-
nificantly improved (PFS; median, 6.2 v 4.2 months; 
HR = 0.79; P = 0.0005) and response rate (43% v 
29%; P , 0.0001). Grade 3/4 neuropathy occurred in 
24% treated with the combination, but was reversible. 
This study confirmed the findings from the Thomas 
trial demonstrating improved PFS and response for 
the  Ixabepilone  +  Capecitabine  combination  com-
pared with Capecitabine alone, although survival was 
equivalent in both groups of patients.
eR/pR/Her2 negative subset of MBc 
patients
Patients with ER/PR/HER2-negative, triple negative 
breast cancer (TNBC) are not candidates for hormonal 
or HER2-targeted therapy and in general do not derive 
as  much  benefit  from  standard  chemotherapy35,37 
agents  approved  for  treatment  of  MBC.  Perez  and 
colleagues38  analyzed  efficacy  and  safety  data  of 
Ixabepilone in patients with TNBC from 5 phase II 
and 2 phase III trials. Of 2,261 patients evaluated in 
these trials 24.5% had TNBC tumors. In the neoadju-
vant setting, Ixabepilone produced a pathologic com-
plete response rate in the breast of 26% in TNBC vs. 
15% in the non-triple-negative population. In patients 
with  MBC  whose  pretreatment  status  ranged  from 
no prior therapy to progression on several classes of 
agents, overall response rates (ORR) in the phase II 
Ixabepilone monotherapy trials ranged from 6 to 55% 
and was similar to patients with non-triple-negative 
tumors. In addition treatment with the combination 
of Ixabepilone + Capecitabine in the phase II study 
resulted in an ORR of 23% in TNBC while ORR of 
31%  was  seen  in  a  preplanned  pooled  analysis  of 
TNBC in the phase III trials of Ixabepilone + Capecit-
abine. The median progression-free survival (PFS) was 
significantly longer for TNBC treated with Ixabepi-
lone  +  Capecitabine  combination  vs.  Capecitabine ixabepilone advanced breast cancer
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alone  (4.2  vs.  1.7  months)  respectively.  Responses 
to Ixabepilone in TNBC are therefore comparable to 
those seen in patients with non-triple-negative tumors 
and  no  apparent  increase  in  toxicity  was  noted  in 
the TNBC subgroup compared with other groups of 
patients.
safety of Ixabepilone
Hematological toxicity
Ixabepilone is contraindicated in patients with a neu-
trophil  count  ,1500  cells/mm3,  with  single  agent 
therapy  myelosuppression  is  dose-dependent  and 
primarily  manifested  as  neutropenia.  Ixabepilone- 
associated hematologic abnormalities (.40%) include 
neutropenia, leukopenia, anemia, and thrombocytope-
nia.  Dose  reductions  are  recommended  in  patients 
who  experience  severe  neutropenia  or  thrombocy-
topenia. Neutropenia-related deaths however are rare 
and occurred in 0.4% of 240 MBC patients treated 
with Ixabepilone as monotherapy. Grade 3/4 neutro-
penia was observed in 54% of patients and leucopenia 
in 49% of patients in one phase II study of Ixabepilone 
monotherapy in MBC but the rate of grade 3 febrile 
neutropenia was 3%.34 Patients should be monitored 
for myelosuppression; frequent peripheral blood cell 
counts  are  recommended  for  all  patients  receiving 
Ixabepilone. Patients who experience severe neutro-
penia  or  thrombocytopenia  should  have  their  dose 
reduced. Neutropenia-related deaths occurred in 1.9% 
of 414 patients with normal hepatic function or mild 
hepatic impairment treated with Ixabepilone in com-
bination with Capecitabine.35
non-Hematological Toxicity
Neurotoxicity
Peripheral neuropathy was common in clinical   trials 
with Ixabepilone although many patients who entered 
these  trials  had  preexisting  peripheral  neuropathy 
due to prior exposure to other neurotoxic chemother-
apy agents (Taxanes).24,35,39,40 In fact prior history of 
peripheral neuropathy did not predict the occurrence 
of  peripheral  sensory  neuropathy  symptoms  in 
patients receiving Ixabepilone. Patients treated with 
IxabepiloIne should be monitored for symptoms of 
neuropathy, such as burning sensation, hyperesthesia, 
hypoesthesia, paresthesia, discomfort, or neuropathic 
pain.  Neuropathy  primarily  sensory  and  peripheral 
due to Ixabepilone tends to occur early during therapy 
and majority of patients (∼75%) develop symptoms 
of new onset or worsening neuropathy during the first 
3 cycles of treatment with Ixabepilone. Patients expe-
riencing new or worsening peripheral neuropathy may 
require dose delays and or dose reductions mentioned 
earlier in this manuscript. In some cases discontinu-
ation of Ixabepilone is necessary due to severe and 
unresolving symptoms. Neuropathy symptoms were 
the most frequent cause of treatment discontinuation 
due to drug toxicity in clinical trials in patients with 
MBC.  Patients  with  other  medical  conditions  with 
higher incidence of preexisting peripheral neuropathy 
such as diabetes mellitus should be approached with 
caution and followed closely while on treatment with 
Ixabepilone as they may have significant worsening of 
their preexisting peripheral neuropathy.
Hypersensitivity reactions
Patients  should  be  premedicated  with  an  histamine 
receptor 1 (H1) and an histamine receptor 2 (H2) antag-
onist approximately 1 hour before Ixabepilone infusion 
and observed for hypersensitivity   reactions (eg, flush-
ing, rash, dyspnea, and bronchospasm).   Premedication 
with corticosteroids in the first cycle is not routinely 
required. In case of severe   hypersensitivity reactions, 
infusion of Ixabepilone should be stopped and aggres-
sive supportive   treatment (eg, epinephrine, corticoster-
oids) started. Patients who experience a hypersensitivity 
reaction in the first cycle of Ixabepilone must be pre-
medicated in subsequent cycles with a corticosteroid in 
addition to the H1 and H2 antagonists, and extension 
of the infusion time can be considered. Ixabepilone 
should be avoided in patients with a known history of 
a severe (CTC grade 3/4) hypersensitivity reaction to 
other agents containing Cremophor EL or its deriva-
tives (eg, polyoxyethylated castor oil).
Cardiac safety
Ixabepilone  is  not  considered  cardiotoxic  however 
caution  should  be  exercised  in  patients  with  a 
  history of cardiac disease and Ixabepilone should be 
  discontinued in patients who develop cardiac ischemia 
or impaired cardiac function while on therapy. Isolated 
reports of cardiovascular adverse reactions such as   
(eg, myocardial ischemia, supraventricular arrhyth-
mia, and ventricular dysfunction) have been reported 
clinical trials with Ixabepilone. Although small the 
frequency of cardiac adverse reactions (myocardial Tkaczuk
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ischemia and ventricular dysfunction) was higher in 
the treatment arm with Ixabepilone in combination 
with Capecitabine (1.9%) as compared to Capecit-
abine monotherapy (0.3%) treatment group.35
Other toxicities
Besides  peripheral  sensory  neuropathy,  the  most 
common adverse reactions (20%) seen in patients 
receiving Ixabepilone were fatigue/asthenia, myalgia/
arthralgia,  alopecia,  nausea,  vomiting,  stomatitis/
mucositis,  diarrhea,  and  musculoskeletal  pain.41 
The following additional adverse events occurred in 
20%  in  combination  with  Capecitabine:  palmar-
plantar  erythrodysesthesia  (hand-foot)  syndrome, 
anorexia,  abdominal  pain,  nail  disorder,  and  consti-
pation.35  Drug-associated  hematologic  abnormalities 
(.40%) include neutropenia, leukopenia, anemia, and 
thrombocytopenia.
Dose reduction of ixabepilone  
and efficacy of therapy
The efficacy data (overall response rate-ORR and dis-
ease free survival-DFS) from the 2 phase III studies 
of  Ixabepilone  with  Capecitabine  vs.  Capecitabine 
were reanalyzed retrospectively looking at the pos-
sible effect of protocol specified, early versus delayed 
or no dose reduction of Ixabepilone due to toxicities.45 
Only patients with measurable disease who received 
4 or more cycles of therapy were analyzed (N = 652), 
the median number of cycles was 7 for both early and 
late/no dose reduction groups. There was no differ-
ence in the ORR (62.6% vs. 52.3%) and median PFS 
Table 3. Phase iii studies with ixabepilone with capecitabine versus capecitabine alone.
phase III studies  
study author
Ixabepilone +  
capecitibine  
versus  
capecitabine
patient  
population
number of 
patients
Response  
rates (%)  
based on  
independent  
review
safety  
GR3/4 toxicities
Thomas eS35 Arm i- ixabepilone  
40 mg/m2, 3 hour 
infusion q 21 d plus  
Capecitabine  
2,000 mg/m2 orally  
on days 1 through  
14 of a 21-day cycle 
Compared to 
Arm ii Capecitabine  
2,500 mg/m2 orally  
on days 1 through  
14 of a 21-day cycle
anthracycline- 
pretreated or  
-resistant and  
taxane-resistant  
locally advanced  
or metastatic 
breast cancer,  
#3 lines of prior  
chemotherapy
752 PFS primary  
endpoint 
5.8 v 4.2 months 
HR 0.75; 95% Ci  
0.64–0.88; 
P = 0.0003 
ORR 
35% v 14%;  
P , 0.0001
ixabepilone + 
Capecitabine v  
Capecitabine 
Sensory neuropathy 
(21% v 0%). 
Fatigue (9% v 3%) 
Neutropenia  
(68% v 11%)
Death as a result  
of toxicity (3% v 1%, 
with patients with liver 
dysfunction [grade 2 
liver function tests] at 
greater risk
Sparano JA36 ixabepilone 40 mg/m2  
intravenously on  
day 1 of 21-day cycle  
plus Capecitabine 
2,000 mg/m2 on  
day 1–14 of a 21-day 
cycle 
Compared to 
Capecitabine  
2500 mg/m2 on  
day 1–14 of a  
21 day cycle
MBC previously  
treated with 
anthracycline  
and taxanes,  
#2 lines  
of prior  
chemotherapy
1221 Primary endpoint  
OS similar for  
both treatment  
arms (median,  
16.4 v 15.6 months; 
HR = 0.9;  
95% Ci, 078 to  
1.03; P = 0.1162) 
PFS; median,  
6.2 v 4.2 months;  
HR = 0.79;  
P = 0.0005) and  
response rate  
(43% v 29%;  
P , 0.0001)  
better for the  
combination treatment
Grade 3 to 4 sensory 
neuropathy in 24% 
treated with the 
combination, reversibleixabepilone advanced breast cancer
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(7.2 vs. 7.0 months) respectively for early vs. late 
or no dose reduction with a HR of 0.98 (0.83–1.17). 
Median duration of response was 5.8 vs. 6.2 months 
respectively.45
Efficacy: single agent Ixabepilone versus 
ixabepilone + Capecitabine doublet
Single agent activity of Ixabepilone in MBC is seen in 
heavily pretreated patients deemed resistant to Taxanes 
and anthracyclines. Several single arm phase II studies 
with different schedules of Ixabepilone and in different 
patient populations with a range of prior exposure to 
chemotherapy were conducted. Not surprisingly prior 
exposure to anthracyclines and taxanes therapy affects 
significantly the potential for response to therapy with 
single  agent  Ixabepilone  in  metastatic  setting  with 
the best responses seen in patients with minimal prior 
exposure to chemotherapy. MBC patients with taxane 
resistant disease have objective response rate (RR) of 
12% (N = 49),39 patients with prior low exposure to 
taxanes and/or resistance have RR = 22% (N = 37),33 
Ixabepilone after adjuvant anthracycline therapy expo-
sure renders RR = 41.5% (N = 65)29; in taxane naïve 
patients RR = 57% (N = 23)31 while in neoadjuvant set-
ting overall complete pathologic response (pCR) rate 
was 18% in breast and 29% in estrogen receptor (ER) 
-negative patients.42
Two  large  phase  III  trials  with  similar  eligibil-
ity criteria included (N = 752 + 1221) patients with 
locally advanced and MBC anthracycline-pretreated 
or resistant and taxane-resistant35,36 and failed to show 
survival benefit for combined therapy with Ixabepi-
lone with Capecitabine as compared to Capecitabine 
alone. Neither trial was designed to allow crossover 
to  Ixabepilone  after  progression  on    Capecitabine. 
The  Sparano  trial  was  powered  to  detect  a  20% 
reduction in the hazard ratio (HR) for death and no 
significant  difference  in  OS  between  the  combi-
nation  (Ixabepilone  +  Capecitabine)  and  Capecit-
abine monotherapy arm was found (median survival 
was 16.4 v 15.6 months; HR = 0.9; 95% CI, 078 to 
1.03; P = 0.1162). In this trial the   treatment arms 
were unbalanced for higher prevalence of impaired 
  performance status (KPS 70% to 80%) in the com-
bination arm (32% v 25%). A secondary Cox regres-
sion  analysis  was  adjusted  for  performance    status 
and other prognostic factors and showed improved 
OS was for the combination (HR = 0.85; 95% CI,   
0.75–0.98; P = 0.0231).36 For both phase III trials PFS 
  and overall response rates were higher in the com-
bination treatment arms as compared to single agent 
therapy with Capecitabine.35,36 Progression free sur-
vival for Ixabepilone + Capecitabine vs Capecitabine 
single agent therapy was (median, 5.8 v 4.2 months) 
for Thomas  trial35  and  (median  6.2  v  4.2  months) 
for Sparano trial.36 The objective response rate was 
also  increased  with  the  combination  in  both  stud-
ies  (35%  v  14%;  P  ,  0.0001)  and  (43%  v  29%; 
P , 0.0001) respectively.
Patient preference
Literature  review  provided  no  published  reports 
on patient self reported preference of therapy with 
single  agent  Ixabepilone  versus  in  combination 
with Capecitabine, however Ixabepilone is gener-
ally well tolerated, and its toxicity profile does not 
overlap  with  that  of  Capecitabine.  Myelosupres-
sion (  leucopenia/neutropeniaI) and peripheral sen-
sory  neuropathy  are  the  most  common  toxicities 
associated with Ixabepilone and can be effectively 
managed  by  dose  reductions  and  delays  where 
appropriate based on the severity of the side-effects. 
Ixabepilone dose reductions are recommended for 
most grade 3 toxicities, excluding transient fatigue, 
arthralgia, and myalgia. Treatment discontinuation 
is recommended for persistent grade 3 neuropathy 
or any grade 4 non  hematological toxicity. Caution 
should be used when treating patients with moderate 
and severe hepatic impairment which is associated 
with greater Ixabepilone exposure and more severe 
toxicity. Patients on concomitant strong cytochrome 
P-450 CYP3A4 inhibitors should have dose adjust-
ments whether Ixabepilone is administered alone or 
in combination with Capecitabine, and whether a 
strong CYP3A4 inhibitor is being coadministered. 
Premedication with H1 and H2 blockers to prevent 
hypersensitivity  reactions  is  required  but  unlike 
with paclitaxel corticosteroid premedication is not 
required unless a hypersensitivity reaction occurred 
previously  with  Ixabepilone  or  during  treatment 
with another Cremophor-containing agent.
conclusions
Ixabepilone a semisynthetic analog of epothilone B 
is the first in class US Food and Drug Administration 
approved member of epothilone class of antineoplastic Tkaczuk
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agents  a  relatively  new  class  of  antimicrotubule 
agents. Ixabepilone is FDA approved for treatment of 
MBC which is resistant to anthracyclines, taxanes and 
Capecitabine and in combination with Capecitabine 
for patients previously exposed to anthrayclines and 
taxanes. Epothilones are cytotoxic macrolides with a 
similar mechanism of action to taxanes but with the 
potential advantage of activity in taxane-resistant set-
tings in preclinical models.18 The antineoplastic activ-
ity of Ixabepilone has been linked to stabilization of 
microtubules, which results in mitotic arrest at the 
G2/M  transition.  Unlike  many  other  antineoplastic 
agents it has low susceptibility to common mecha-
nisms of tumor resistance, including those mediated 
by  P-glycoprotein  a  multidrug  resistance  protein. 
In addition the microtubule-stabilizing agents such as 
Ixabepilone prolong activation of the spindle assem-
bly checkpoint which may promote cancer cell death 
in mitosis or following mitotic exit.19
Ixabepilone is metabolized in the liver and caution 
should be used when considering patients with liver 
impairment for therapy with this agent. Ixabepilone 
exposure is greater in patients with hepatic impairment 
and those receiving concomitant strong cytochrome 
P-450  CYP3A4  inhibitors.  Dose  adjustments  and 
restrictions are recommended according to the degree 
of hepatic impairment, whether Ixabepilone is admin-
istered alone or in combination with Capecitabine if a 
strong CYP3A4 inhibitor is being coadministered.24
Various  schedules  of  single  agent  Ixabepilone 
were studied in phase I, dose escalation studies to 
assess maximum tolerated dose, dose limiting toxic-
ity and pharmacokinetic and pharmacodynamic pro-
file of Ixabepilone in solid tumor malignancies and 
lymphomas. The following schedules of Ixabepilone 
were tested 1 and 3 hour infusion once every 21 days, 
30 minutes weekly infusion continuous on 21 day 
schedule without interruption, weekly, 1 hour infusion 
3 out of 4 weeks every 28 days, daily infusion on days 
1–3 and 1–5, every 21 days (Table 1). All schedules 
mentioned above showed acceptable and manageable 
side-effect profiles.
Ixabepilone was also extensively studied in   several 
phase II studies (Table 2) as a single agent in patients 
with MBC and was found to be effective and well toler-
ated with a predictable and manageable safety profile. 
Not surprisingly prior exposure to anthracyclines and   
taxanes therapy affects significantly the potential for 
response  to  therapy  with  single  agent  Ixabepilone 
in  metastatic  setting.  MBC  patients  with  taxane 
resistant disease have objective response rate (RR) 
of  12%,  patients  with  prior  low  exposure  to  tax-
anes and/or resistance RR = 22%, Ixabepilone after 
adjuvant  anthracycline  therapy  exposure  renders 
RR = 42% and in taxane naïve patients RR = 57%.
Effective treatment options for patients with MBC 
resistant to anthracyclines and taxanes are limited. 
Ixabepilone has single-agent activity in this patient 
population and preclinical synergy with Capecitabine 
has been demonstrated.35 Two large phase III trials 
(N = 752 + 1221) in patients with locally advanced 
and MBC  anthracycline-pretreated or  resistant and 
taxane-resistant35,36 were conducted to evaluate effi-
cacy of Ixabepilone 40 mg/m2 as 3 hour infusion every   
3 weeks in combination with Capecitabine 2000 mg/m2 
total daily dose total daily dose, in both trials the control 
arm consisted of Capecitabine 2500 mg/m2 total daily 
dose in 2 divided doses on days 1–14 of a 21 day treat-
ment cycle. Neither trial was designed to allow cross-
over to single agent Ixabepilone treatment at the time 
of progression on Capecitabine and both trials failed 
to show survival benefit for combined therapy with 
Ixabepilone + Capecitabine as compared to Capecit-
abine  alone.  Progression  free  survival  and  overall 
response rates were higher in the combination treat-
ment arms as compared to single agent therapy with 
Capecitabine. Ixabepilone + Capecitabine PFS rela-
tive to Capecitabine was (median, 5.8 v 4.2 months) 
for Thomas trial35 and (median 6.2 v 4.2 months) for 
Sparano trial.36 The objective response rate was also 
increased with the combination in both studies (35% 
v 14%; P , 0.0001) and (43% v 29%; P , 0.0001) 
respectively.
Responses  to  Ixabepilone  in  triple-negative 
MBC are comparable to those seen in patients with 
non-triple-negative tumors and no apparent increase 
in  toxicity  was  noted  in  the  triple-negative  sub-
group compared with other groups of patients. Treat-
ment with Ixabepilone + Capecitabine in the phase 
II study resulted in an overall response rate (ORR) 
of 23% in TNBC while ORR of 31% was seen in a 
preplanned pooled analysis of TNBC in the phase III 
trials  of    ixabepilone  +  Capecitabine.  Significantly 
prolonged median PFS was seen for TNBC treated 
with the combination of Ixabepilone + Capecitabine 
compared to Capecitabine alone 4.2 vs. 1.7 months ixabepilone advanced breast cancer
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respectively.38  Ixabepilone  as  single  agent  therapy 
appears  to  show  excellent  antitumor  activity  in 
patients with triple-negative MBC and the addition of 
Ixabepilone to Capecitabine results in approximately 
doubling in median PFS for TNBC patients versus 
Capecitabine alone.
Literature review provided no published reports 
on patient self reported preference of therapy with 
single agent Ixabepilone versus in combination with 
Capecitabine, however Ixabepilone is generally well 
tolerated, and its toxicity profile does not overlap with 
that of Capecitabine and therefore depending on prior 
exposure to chemotherapy both single agent Ixabepi-
lone or in combination with Capecitabine can be used 
safely.  Myelosupression  (leucopenia/neutropeniaI) 
and peripheral sensory neuropathy are the most com-
mon toxicities associated with Ixabepilone and can 
be effectively managed by dose reductions and delays 
where appropriate based on the severity of the side- 
effects. In addition recent reports indicate that early 
into  treatment  Ixabepilone  dose  reductions  do  not 
affect the efficacy of this agent and certainly should 
be considered when required based on the observed   
side-effects.
In summary Ixabepilone as single agent or in com-
bination with Capecitabine is an effective therapy for 
MBC  which  is  anthracycline  and  taxane  resistant. 
Significant activity is seen in ER, PR, HER2 negative 
TNBC patients with MBC. As expected the efficacy 
of  Ixabepilone  is  higher  in  less  heavily  pretreated 
patients and this agent can be considered in these 
settings.
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